UCB (UCBJY) Stock Price, News & Analysis

Company Overview

UCB SA is a Belgium-based biopharmaceutical company that discovers, develops and commercializes medicines for severe diseases, with a primary focus on neurology and immunology. The company serves patients and healthcare professionals in markets around the world through its research, manufacturing and commercial operations.

UCB’s medicines include Bimzelx (bimekizumab), used to treat several inflammatory conditions; Cimzia (certolizumab pegol), an immunology therapy; and Fintepla (fenfluramine), a treatment for certain severe epileptic syndromes. Its neurology portfolio also includes Briviact (brivaracetam) and Nayzilam (midazolam) for epilepsy-related care, among other products and therapies.

The company traces its origins to 1928, when it was established in Belgium as Union Chimique Belge. UCB has since evolved from a diversified chemical and pharmaceutical business into a focused biopharmaceutical company, with activities spanning research and development, clinical studies, regulatory affairs and the global commercialization of specialty medicines.

Key Stats

• Today's Range: $114.23 to $115.28
• 50-Day Range: $110.78 to $130.83
• 52-Week Range: $110.55 to $168.76
• Volume: 70,568 shs
• Average Volume: 52,063 shs
• Market Capitalization: $43.25 billion
• P/E Ratio: N/A
• Dividend Yield: 0.46%
• Price Target: N/A
• Consensus Rating: Moderate Buy

UCB Stock Analysis - MarketRank™

UCB scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

UCB has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

UCB has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 14.89%

Earnings Growth

Earnings for UCB are expected to grow by 14.89% in the coming year, from $6.85 to $7.87 per share.

Price to Earnings Growth Ratio

UCB has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of UCB has been sold short.

Short Interest Ratio / Days to Cover

UCB has a short interest ratio ("days to cover") of 0.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in UCB has recently decreased by 73.70%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

UCB has a dividend yield of 0.45%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

UCB does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, UCB will have a dividend payout ratio of 6.73% next year. This indicates that UCB will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.04

News Sentiment

UCB has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for UCB this week, compared to 0 articles on an average week.

MarketBeat Follows

3 people have added UCB to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, UCB insiders have not sold or bought any company stock.

Percentage Held by Institutions

UCB has minimal institutional ownership at this time.

Company Calendar

• Today: 10/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:UCBJY
• Previous Symbol: OTCMKTS:UCBJY
• CIK: 1290640
• Web: www.ucb.com
• Phone: (322) 559-9999
• Fax: 32-2559-9900
• Employees: 10,117
• Year Founded: 1928

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 16.70
• P/E Growth: 0.96
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $8.76 billion
• Price / Sales: 4.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 378,040,000
• Free Float: N/A
• Market Cap: $43.25 billion
• Optionable: Not Optionable
• Beta: 0.46